TransEnterix (NYSEAMERICAN:TRXC) Shares Gap Up to $0.43

TransEnterix, Inc. (NYSEAMERICAN:TRXC) gapped up before the market opened on Thursday . The stock had previously closed at $0.42, but opened at $0.43. TransEnterix shares last traded at $0.44, with a volume of 2,743,283 shares.

Several research firms have weighed in on TRXC. Royal Bank of Canada cut shares of TransEnterix from an “outperform” rating to a “sector perform” rating and set a $1.00 price objective on the stock. in a research report on Thursday, August 8th. Zacks Investment Research lowered shares of TransEnterix from a “hold” rating to a “sell” rating in a research note on Thursday, October 10th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company. TransEnterix currently has an average rating of “Hold” and a consensus price target of $2.62.

TransEnterix (NYSEAMERICAN:TRXC) last issued its earnings results on Wednesday, August 7th. The medical instruments supplier reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.01). The business had revenue of $3.64 million for the quarter, compared to the consensus estimate of $5.13 million.

Several hedge funds have recently added to or reduced their stakes in TRXC. Paloma Partners Management Co acquired a new position in TransEnterix during the 2nd quarter worth $27,000. Tradewinds Capital Management LLC increased its holdings in shares of TransEnterix by 1,222.2% during the 2nd quarter. Tradewinds Capital Management LLC now owns 23,800 shares of the medical instruments supplier’s stock worth $32,000 after purchasing an additional 22,000 shares during the period. Brown Advisory Inc. bought a new position in shares of TransEnterix during the 2nd quarter worth about $91,000. A.R.T. Advisors LLC bought a new stake in TransEnterix in the second quarter valued at about $108,000. Finally, Prospera Financial Services Inc bought a new stake in TransEnterix in the second quarter valued at about $195,000.

About TransEnterix (NYSEAMERICAN:TRXC)

TransEnterix, Inc, a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe.

Recommended Story: What is a Special Dividend?

Receive News & Ratings for TransEnterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransEnterix and related companies with MarketBeat.com's FREE daily email newsletter.